IP Library Patent Application 14837750
Patent Application
App. No. 14/837,750

Modified Pectins, Compositions and Methods Related Thereto

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/837,750
Abstract

The present invention provides compositions of modified pectin and methods for preparing and using them.

Claims (56)

1 - 41 . (canceled)

42 . A method of treating cancer in a patient in need thereof, comprising parenterally administering to the patient a therapeutically effective amount of an aqueous solution of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the solution is substantially free of modified pectins having molecular weights below 25 kD.

43 . The method of claim 42 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 50-200 kD.

44 . The method of claim 43 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 70-150 kD.

45 . A method of treating cancer in a patient in need thereof, comprising parenterally administering to the patient a therapeutically effective amount of an aqueous solution of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 70-150 kD.

46 . The method of claim 45 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-150 kD.

47 . The method of claim 46 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 80-100 kD.

48 . The method of claim 45 , wherein the aqueous solution is substantially free of modified pectins having molecular weights below 25 kD.

49 . The method of claim 42 , wherein the solution contains at least 0.5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

50 . The method of claim 49 , wherein the solution contains at least 5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

51 . The method of claim 45 , wherein the solution contains at least 0.5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

52 . The method of claim 51 , wherein the solution contains at least 5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

53 . The method of claim 42 , wherein the aqueous solution comprises a deesterified and partially depolymerized modified pectin.

54 . The method of claim 45 , wherein the aqueous solution comprises a deesterified and partially depolymerized modified pectin.

55 . The method of claim 42 , wherein the aqueous solution comprises a modified pectin.

56 . The method of claim 45 , wherein the aqueous solution comprises a modified pectin.

57 . The method of claim 55 , wherein the modified pectin consists essentially of a homogalacturonan backbone with small amounts of rhamnogalacturonan therein, wherein the backbone has neutral sugar side chains having a low degree of branching dependent from the backbone.

58 . The method of claim 57 , wherein the galacturonic acid subunits of the backbone have been substantially deesterified.

59 . The method of claim 56 , wherein the modified pectin consists essentially of a homogalacturonan backbone with small amounts of rhamnogalacturonan therein, wherein the backbone has neutral sugar side chains having a low degree of branching dependent from the backbone.

60 . The method of claim 59 , wherein the galacturonic acid subunits of the backbone have been substantially deesterified.

61 . The method of claim 42 , wherein parenterally administering comprises injection or intravenous infusion.

62 . The method of claim 45 , wherein parenterally administering comprises injection or intravenous infusion.

63 . A method of treating cancer in a patient in need thereof, comprising administering to the patient a liquid composition comprising colloidal particles of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the colloidal particles of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin consist essentially of colloidal particles which are less than 1 micron in diameter and the composition is substantially free of modified pectins having molecular weights below 25 kD.

64 . The method of claim 63 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-150 kD.

65 . The method of claim 64 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-100 kD.

66 . The method of claim 63 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 50-200 kD.

67 . The method of claim 66 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 70-150 kD.

68 . The method of claim 63 , wherein the composition is an aqueous solution.

69 . The method of claim 68 , wherein the solution contains at least 0.5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.

70 . The method of claim 69 , wherein the solution contains at least 5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.

71 . The method of claim 63 , wherein the composition is a colloidal suspension.

72 . The method of claim 63 , wherein the colloidal particles are less than 0.20 μm in diameter.

73 . The method of claim 63 , wherein the composition comprises a purified modified pectin.

74 . The method of claim 63 , wherein the composition comprises a purified, deesterified, and partially depolymerized modified pectin.

75 . The method of claim 63 , wherein the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin inhibits cancer proliferation with an IC 50 less than 200 μg/mL.

76 . The method of claim 75 , wherein the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin inhibits cancer proliferation with an IC 50 in the range of 25-75 μg/mL.

77 . The method of claim 63 , wherein the composition is a dosage form selected from dosage forms suitable for oral dosage, topical application, and inhalation.

78 . The method of claim 77 , wherein the dosage form is suitable for oral dosage.

79 . The method of claim 63 , wherein the composition is a dosage form suitable for parenteral administration.

80 . The method of claim 79 , wherein the parenteral administration is selected from injection or intravenous infusion.

81 . The method of claim 63 , wherein the composition is a colloidal solution.

82 . A method of treating cancer in a patient in need thereof, comprising administering to the patient a liquid composition comprising colloidal particles of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the colloidal particles of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin consist essentially of colloidal particles which are less than 1 micron in diameter and the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 70-150 kD.

83 . The method of claim 82 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-150 kD.

84 . The method of claim 83 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-100 kD.

85 . The method of claim 82 , wherein the composition is an aqueous solution.

86 . The method of claim 85 , wherein the solution contains at least 0.5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.

87 . The method of claim 86 , wherein the solution contains at least 5% by weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin.

88 . The method of claim 85 , wherein the composition is a colloidal solution.

89 . The method of claim 82 , wherein the composition is a colloidal suspension.

90 . The method of claim 82 , wherein the colloidal particles are less than 0.20 μm in diameter.

91 . The method of claim 82 , wherein the composition comprises a purified modified pectin.

92 . The method of claim 82 , wherein the composition comprises a purified, deesterified, and partially depolymerized modified pectin.

93 . The method of claim 82 , wherein the composition is a dosage form selected from dosage forms suitable for oral dosage, topical application, and inhalation.

94 . The method of claim 93 , wherein the dosage form is suitable for oral dosage.

95 . The method of claim 82 , wherein the composition is a dosage form suitable for parenteral administration.

96 . The method of claim 95 , wherein the parenteral administration is selected from injection or intravenous infusion.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 037018 FRAME: 0668. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2016
From: PROSPECT THERAPEUTICS, INC.
To: TANG CAPITAL PARTNERS LP
Reel/Frame 039312/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2015
From: TANG CAPITAL PARTNERS, LP
To: SOLANA THERAPEUTICS, INC.
Reel/Frame 036926/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2015
From: GLYCOGENESYS, INC.
To: MARLBOROUGH RESEARCH AND DEVELOPMENT INC.
Reel/Frame 036926/0533 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2015
From: STAPLES, MARK; ROLKE, JAMES
To: GLYCOGENESYS, INC.
Reel/Frame 036926/0609 →
MERGER AND CHANGE OF NAME Recorded Oct 30, 2015
From: LJPC MERGER SUB, INC.; LA JOLLA PHARMACEUTICAL COMPANY
To: LA JOLLA PHARMACEUTICAL COMPANY, INC.
Reel/Frame 036926/0636 →
MERGER Recorded Oct 30, 2015
From: LA JOLLA PHARMACEUTICAL COMPANY
To: LJPC MERGER SUB, INC.
Reel/Frame 036926/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2015
From: PROSPECT PHARMACEUTICALS, INC.
To: TANG CAPITAL PARTNERS LP
Reel/Frame 037018/0668 →
CHANGE OF NAME Recorded Oct 30, 2015
From: PROSPECT PHARMACEUTICALS, INC.
To: PROSPECT THERAPEUTICS, INC.
Reel/Frame 037018/0679 →
CHANGE OF NAME Recorded Oct 30, 2015
From: MARLBOROUGH RESEARCH AND DEVELOPMENT INC.
To: PROSPECT PHARMACEUTICALS, INC.
Reel/Frame 037018/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2015
From: SOLANA THERAPEUTICS, INC.
To: LA JOLLA PHARMACEUTICAL COMPANY
Reel/Frame 036926/0669 →